Regeneron Pharmaceuticals, Inc.

Yale University

Institute for Research in Biomedicine

Tim Willinger

Andrew J Murphy

George D Yancopoulos

Sean Stevens

Richard A Flavell

Markus G Manz

Anthony Rongvaux

Elizabeth Eynon

Till Strowig

Jorge Galan

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g.,oris described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Genetically modified mice and engraftment

The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.

Genetically modified non-human animals and methods of use thereof

Growing community of inventors

Ultran, Sweden

Tim Willinger